Technical Analysis for PULM - Pulmatrix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 1.89 | -0.01% | 0.00 |
PULM closed down 0.01 percent on Wednesday, May 8, 2024, on 21 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
Earnings due: May 10
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Flat | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Support | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
20 DMA Resistance | Bearish | -0.01% | |
Crossed Above 50 DMA | Bullish | -0.01% | |
Fell Below 50 DMA | Bearish | 1.61% | |
Gapped Down | Weakness | 1.61% | |
Fell Below 20 DMA | Bearish | -3.58% | |
Fell Below 200 DMA | Bearish | -3.58% | |
Inside Day | Range Contraction | -3.58% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Gap Up Closed | about 12 hours ago |
Reversed from Up | about 12 hours ago |
Gap Up Partially Closed | about 14 hours ago |
Gapped Up (Partial) | about 15 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its iSPERSE technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease and other treatments. Pulmatrix, Inc. is based in Lexington, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Clinical Development Rare Diseases Chronic Obstructive Pulmonary Disease Idiopathic Pulmonary Fibrosis Cystic Fibrosis Pulmonary Disease Pulmonary Fibrosis Pulmonology Treatment Of Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Rehabilitation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Clinical Development Rare Diseases Chronic Obstructive Pulmonary Disease Idiopathic Pulmonary Fibrosis Cystic Fibrosis Pulmonary Disease Pulmonary Fibrosis Pulmonology Treatment Of Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Rehabilitation
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.979 |
52 Week Low | 1.55 |
Average Volume | 14,389 |
200-Day Moving Average | 2.01 |
50-Day Moving Average | 1.88 |
20-Day Moving Average | 2.00 |
10-Day Moving Average | 1.94 |
Average True Range | 0.13 |
RSI (14) | 47.09 |
ADX | 17.04 |
+DI | 19.21 |
-DI | 16.24 |
Chandelier Exit (Long, 3 ATRs) | 1.82 |
Chandelier Exit (Short, 3 ATRs) | 2.18 |
Upper Bollinger Bands | 2.18 |
Lower Bollinger Band | 1.82 |
Percent B (%b) | 0.19 |
BandWidth | 17.62 |
MACD Line | 0.00 |
MACD Signal Line | 0.03 |
MACD Histogram | -0.022 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.04 | ||||
Resistance 3 (R3) | 2.04 | 2.00 | 2.01 | ||
Resistance 2 (R2) | 2.00 | 1.96 | 1.99 | 2.01 | |
Resistance 1 (R1) | 1.94 | 1.93 | 1.92 | 1.94 | 2.00 |
Pivot Point | 1.90 | 1.90 | 1.89 | 1.89 | 1.90 |
Support 1 (S1) | 1.84 | 1.86 | 1.82 | 1.84 | 1.78 |
Support 2 (S2) | 1.80 | 1.83 | 1.80 | 1.77 | |
Support 3 (S3) | 1.74 | 1.80 | 1.77 | ||
Support 4 (S4) | 1.74 |